Having experienced Covid twice, including long term symptoms, Amitava is now researching the effect of covid long term.

I am leading the team conducting the Stimulate-ICP (Symptoms, trajectory, inequalities and management: understanding long Covid to address and transform existing integrated care pathways) study, which involves a trial to evaluate a community-based, comprehensive MRI scan to rule out multi-organ impairment caused by Covid-19 and digitally enhanced rehabilitation, including tailored information and recovery plans, and connection to relevant specialists through an app, which will inform future care. Another trial will repurpose existing drugs, including antihistamines (loratadine and famotidine), anticoagulants (rivaroxaban) and anti-inflammatories (colchicine) to measure effects of three months’ treatment on long Covid symptoms, mental health, return to work and other important outcomes.

Further details on his research can be found in his article, published in the Guardian:

I’m leading a long Covid trial – it’s clear Britain has underestimated its impact by Amitava Banerjee

We wish Amitava luck with his research.